In the Aa-chain gene coding for an abnormal fibrinogen (fibrinogen Marburg) we identified a single base substitution (A + T) that changes the codon Aa 461 AAA (Lys) to TAA (Stop). The propositus was found to be homozygous for the mutation, whereas the father and five siblings were heterozygous, and three other siblings contained only the normal sequence. The stop codon at position 461 results in the deletion of the carboxyl-terminal segment Aa 461-610. Purified fibrinogen Marburg contained an Arrchain with a relative molecular weight of approximately 47,000. The FpA release by thrombin was not affected by this deletion, whereas the fibrin polymerization was strongly decreased. The binding of endothelial cells to immobilized fibrinogen Marburg was almost completely abolished compared with normal fibrino-IBRIN FORMATION begins with the thrombin-F catalyzed release of fibrinopeptide A (FpA) from the amino-terminus of the Act-chains of fibrinogen. The cleavage of FpA and fibrinopeptide B (FpB) results in the exposure of polymerization sites in the amino-terminal part of fibrinogen, designated "A" and "B" sites, respectively.' Complementary polymerization sites to the "A" and "B" sites, designated "a" and "b," are located in the carboxylterminal region of the fibrinogen molecule.' Assembly of the mature three-dimensional fibrin matrix starts with the formation of double-stranded fibril@ followed by branching and lateral association of these fibril^.^-^ The initial fibrin formation arises predominantly from the interaction between the "A" and "a" sites: while lateral association is more dependent on the interaction between the "B" and "b" site^.^,^ The carboxyl-terminus of the Aa-chain is thought to play an important role in the branching and lateral association step of fibrin formation.I0 In addition to being a precursor of fibrin, fibrinogen also binds to several cell types, of which platelets and endothelial cells are the best studied. This binding is mediated through the interaction of a fibrinogen-specific receptor on the membrane of these c e W with distinct sites on the fibrinogen molecule. It has recently been suggested that the Arg-Gly-Asp contain- gen. Fibrinogen Marburacontained a substantial amount of albumin linked to the fibrinogen molecule by disulfide bonds, and these fibrinogen-albumin complexes were also present in plasma. The plasma fibrinogen concentration of the propositus was measured by three different methods: a functional method (e0.25 mg/mL), an immunologic method using polyclonal antibodies (0.6 mg/mL), and an immunologic method based on two monoclonal antibodies specific for the amino-terminus and carboxyl-terminus of the APchain (<0.05 mg/mL). Using the two immunologic methods, it appeared that only 10% to 15% of the plasma fibrinogen of the heterozygous siblings was abnormal.
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ing sequence in the carboxyl-terminus of the Act-chain (Act 572-574) is the major site that interacts with the integrin avo3 on endothelial cells.12
Of the 76 structurally identified congenitally abnormal fibrinogens, 73 showed a single amino acid substitution and two showed a deletion in the fibrinogen m01ecule.l~ From the cases with known structural defects, 68 are heterozygous for the molecular defect, while eight are homozygous. Molecular defects introducing additional cysteines by amino acid substitutions are described in 25 cases. In fibrinogens MetzI4 and K a w a g u~h i~~ (Aa 16 Arg -+ Cys), Seattle 116 and Christchurch 1117 (BP 14 Arg -+ Cys) intramolecular disulfide bond formation between two abnormal chains was suggested. In fibrinogen Osaka I1 (y 275 Arg + Cys) the additional Cys was linked to a free cysteine molecule.18 Recently, fibrinogen-albumin complexes were detected in fibrinogens IJmuiden (BP 14 Arg -+ Cys) and Nijmegen (BP 44 Arg + Cys).I9 Congenital dysfibrinogenemias associated with a low plasma fibrinogen concentration are described in 24 cases with unknown structural defects. 13 The present report describes the structural defect in the previously reported fibrinogen Marburg20 inferred from DNA analysis (Aa 461 AAA [Lys] + TAA [Stop]). Evidence is presented that this mutation affects fibrin polymerization and prevents the binding of fibrinogen Marburg to endothelial cells. Furthermore, disulfide-linked fibrinogenalbumin complexes are detected in the plasma of the propositus.
MATERIALS AND METHODS
Parameters determined in plasma. Blood was collected by venepuncture and anticoagulated with 1/10 vol of 0.11 mol/L trisodium citrate. Plasma was prepared by centrifugation of the blood at 2,300g for 30 minutes at 4°C. Thrombin and Reptilase (Boehringer Mannheim, Mannheim, Germany) clotting times were performed as described.21 Fibrin(ogen) degradation products were measured in plasma using a monoclonal antibody (MoAb) based immunoassay. 22 The functional plasma fibrinogen concentration was determined according to C l a~s s . *~ The immunologic fibrinogen concentration was determined by radial immunodiffusion according to Mancini et al." The plasma fibrinogen concentration was also measured by two enzyme immunoassays (EIA) using an MoAb specific for the amino-terminus of the human fibrinogen Aa-chain
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(MoAb Y1825) as capture antibody. The bound fibrinogen was detected by rabbit antifibrinogen IgGs conjugated with horseradish peroxidase (HRP) (r-a-Fbg/HRPZ2) or with an MoAb specific for the carboxyl-terminus of the fibrinogen Aa-chain conjugated with HRP (MoAb G8/HRPZ6). The assays were performed by incubating microtiter plates (655001; Greiner, Alphen a/d Rijn, The Netherlands) with 0.12 mL per well of MoAb Y18 dissolved in phosphate-buffered saline (PBS) to a concentration of 3 pg/mL for 16 hours at 4°C. The coated plates were washed three times with PBS containing 0.05% Tween 20 (PBS/Tween), after which 0.1 mL of plasma diluted in PBS/Tween was added to the wells and incubated for 30 minutes at room temperature. After washing three times with PBS/Tween, 0.1 mL of r-a-Fbg/HRP or MoAb G8/HRP was added to the wells. The plates were incubated for 60 minutes at room temperature and washed four times with PBS/ Tween, after which 0.2 mL of substrate solution containing 3,3',5,5'-tetramethyI benzidine (TMB) and H20227 was added. The reaction was stopped by adding 50 pL of 2 mol/L H2S04, and the absorbance at 450 nm was measured on a multiscan (Flow Laboratories, Irvine, England). Pooled plasma containing 2.5 mg/mL fibrinogen, determined gra~imetrically,2~ was used as a standard in all fibrinogen assays.
Fibrinogen was purified from plasma by precipitation with p-alanine essentially as described by Straughn and Wagner.28 p-Alanine was added to plasma to a final concentration of 1 mol/L and incubated on ice for 30 minutes. The precipitate was removed by centrifugation for 30 minutes at 3,0008, 4°C. To the supernatant, p-alanine was added to a final concentration of 3.0 mol/L and incubated for 60 minutes on ice. The precipitated fibrinogen was collected by centrifugation for 30 minutes at 10,000g 4°C and dissolved in 0.15 mol/L NaCI, 5 mmol/L trisodium citrate solution. The fibrinogen was reprecipitated by adding p-alanine to a final concentration of 3.0 mol/L and incubating for 30 minutes on ice. The fibrinogen was collected by centrifugation for 30 minutes at 10,OOOg 4°C and dissolved in 0.05 mol/L Tris/HCl pH 7.5 to a concentration of approximately 2 mg/mL. After dialyses against 0.05 mol/L Tris/HCI pH 7.5 for 16 hours at 4"C, contaminating fibronectin was removed by adsorption to gelatin-sepharose (Pharmacia, Uppsala, Sweden).29 The yield of this purification was approximately 60% for normal fibrinogen and only 20% for fibrinogen Marburg. The low yield for fibrinogen Marburg was due to the fact that a substantial amount of fibrinogen Marburg did not precipitate at a concentration of 3.0 mol/L p-alanine.
Fibrinogen solutions were first dialyzed against 0.1 mol/L Tris/HCI pH 7.5, containing 1 mmol/L CaC12 or 1 mmol/L EDTA, and the fibrinogen concentration, determined by measuring the absorbance at 280 nm (A1%Jcm = 15.0), was adjusted to 0.2 mg/mL. To initiate coagulation, 10 pL of thrombin (10 National Institutes of Health [NIH] U/mL; Leo, Ballerup, Denmark) solution was added to 0.7" aliquots of these fibrinogen solutions. Coagulation of purified fibrinogen was measured as absorbance at 350 nm as a function of time using a spectrophotometer (Pye Unicam SP 1700, Cambridge, UK).
FpA release from purified fibrinogen by thrombin was determined by radioimmunoassay (Mallinckrodt Diagnostics, Maryland Heights, MO). Fibrinogen was diluted to 0.1 mg/mL with 0.05 mol/L Tris/HCl pH 7.5, and to 100 JLL of this fibrinogen solution, 25 pL of thrombin solution (0.05 NIH U/mL; Leo) was added. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) ofpuri$ed fibrinogen andplasma. SDS-PAGE of purified fibrinogen and plasma after reduction with 2-mercaptoethanol was performed on 10% gels according to L a e~n m l i .~~ Electrophoresis of plasma without reduction was performed on 2% to 16% precast gradient gels (Pharmacia). The electrophoresis buffer contained 0.04 mol/L Tris, 0.02 mol/L sodium acetate, 0.002 mol/L EDTA, 0.2% wt/vol SDS, pH 7.4, while the sample buffer contained 0.01 mol/L TrislHCI, 0.001 mol/L EDTA, 1% wt/vol SDS, pH 8.0.
After separation on the SDS-PAGE gels, proteins were electroblotted onto nitro~ellulose~~ for 16 hours at 400 mA and 10°C. The blots were blocked by incubation with 0.01 mol/L Tris/HCl pH 7.4, 0.15 mol/L NaCI, 0.5% (wt/vol) gelatin, and 0.05% (vol/vol) Tween 20 for 2 hours at room temperature. All antibodies were diluted with 0.01 mol/L Tris/HCl pH 7.4, 0.15 mol/L NaCl, 0.05% (vol/vol) Tween 20. MoAb Y18/HRP, goat antihuman albumin conjugated to HRP (g-a-albumin/HRP; Nordic, Tilburg, The Netherlands), and r-a-Fbg/HRP were diluted 1:2,000, 1:2,500 and 1:300, respectively. The blots were incubated for 2 hours with the antibody solutions at room temperature, and subsequently washed five times for 10 minutes with dilution buffer. Cross-reacting bands were visualized by incubation with 4-chloro-lnaphthol?* Genomic DNA was isolated from blood cells as described p r e v i o~s l y .~~ Oligonucleotides d a (S'TGGGGCACATTTGAAGAGGTGT-CA 3') and a5b (5'GGAACTTACAGTCGACCACAAAAACA-GACC 3') were used to amplify the part of the Aa-chain gene, coding for amino acid 391 to 625 and 121 bp of 3' untranslated sequence.34 Amplification by PCR35 was performed in a 100-pL reaction volume containing 1 pg genomic DNA, 0.2 mmol/L each of dATP, d(JTP, dGTP, and dTTP, 0.2 pmol/L each of primer a5a and a5b in 1X reaction buffer (10 mmol/L Tris/HCl pH 8.3 at 25"C, 50 mmol/L KCl, 3.0 mmol/L MgC12, and 0.001% (wt/vol gelatin). The DNA was denatured at 94°C for 4 minutes and 2.0 U Taq DNA polymerase was added. Cycles consisted of a 1-minute 9 4 T , 0.5-minute 58"C, and 1.5-minute 72°C incubation. After 30 cycles, the amplified DNA was precipitated with ethanol, dried, dissolved in 20 pL distilled water, and run on a 1% (wt/vol) ultra low gelling agarose (A-5030; Sigma). The band with the appropriate size, as predicted by the cDNA sequence of the Aa-chain gene,34 was cut out of the gel in a volume of approximately 20 pL and heated to 55°C. One microliter of the melted agarose was mixed with 1 pL of primer d a (60 ng) and 2 pL of 5X annealing buffer (T7 sequence kit; Pharmacia), and the volume was brought up to 10 p L with distilled water. The mixture was heated to 95°C for 3 minutes and put on ice immediately thereafter. Labeling (5 minutes) and termination (10 minutes) reactions were performed using the T7 DNA sequence kit (Pharmacia) according to the manufacturer's instructions.
Detection of mutation in family members by restriction analysis. PCR samples of the family members containing the Aa-fragment were incubated with the restriction endonuclease Dde I (New England Biolabs, Beverly, MA). After incubation, the restriction digests were analyzed on a 2% (wt/vol) agarose gel (A-6013; Sigma) and stained with ethidium bromide. DNA molecular size markers were prepared by h a I digestion of M13mp18 DNA.
Free sulfhydryl groups in fibrinogen were determined using 5,5'-dithiobis(2-nitrobenzoic acid) (DTNB)?6 Purified fibrinogen was dissolved to 5 mg/mL in 0.05 mol/L Tris/HC1 pH 8.2 containing 1 mmol/L EDTA and 8 mol/L urea.37 Five microliters of a 10 mmol/L DTNB solution was added to 0.5 mL of the fibrinogen solution and the
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RESULTS
A 20-year-old woman suffered from a uterine hemorrhage after delivery of her first child by Caesarian section. The patient received 2 L fresh blood during the operation. On the seventh postoperative day a pulmonary embolism occurred, for which the patient was treated with phenprocoumon. Embolism occurred repetitiously and the patient developed a deep pelvic thrombosis:..A second pelvic thrombosis developed at the 36th postoperative day, followed by a third after the patient's dismissal from the hospital. T h e mother of the patient had died of apoplexia after a long period of hypertension. All other family members did not show any Clinical and laboratory data.
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A a clinical symptoms. The laboratory studies on the plasma of the propositus (Table 1) showed severely prolonged thrombin and Reptilase clotting times compared with normal plasma. The functional fibrinogen value was lower than the immunologic value and the immunologic value itself was much lower than that of normal plasma. SDS-PAGE and immunoblot analjsis of purified fibrinogen and plasma. Purified fibrinogen Marburg analyzed after reduction by SDS-PAGE on a 10% gel according to Laemmli (Fig lA, lane 2) showed a very faint Coomassiestained band at the Aa-chain position of normal fibrinogen (lane 1). Immunoblot analysis using r-a-Fbg/HRP showed that this faint band did not cross-react with the antibody against fibrinogen (Fig lB, lane 2) , indicating that the protein was not related to fibrinogen. Furthcrmore, the y-chain band in fibrinogen Marburg (Fig lB, lane 2) is more intense than the corresponding band in normal fibrinogen (lane 1). Two additional faint bands with M+ smaller than normal y-chain are present in fibrinogen Marburg. Incubation of the blots with MoAb Y W H R P , specific for the amino-terminus of the A a -~h a i n ?~ showed that the Aachain of fibrinogen Marburg (Fig lC, lane 2) had the same electrophoretic mobility as the y-chain of normal fibrinogen (lane 1). The additional bands in fibrinogen Marburg also reacted with MoAb Y18/HRP (Fig lC, lane 2) , indicating that these bands were degraded Aa-chains. Normal fibrinogen also shows degradation of the Aa-chain (Fig lC, lane Figure 1D shows that the faint Coomassie-stained band present in fibrinogen Marburg at the position of normal A a t h a i n (Fig 1 A, lane 2) cross-reacts with the g-a-albumin/ H R P conjugate. This indicates that fibrinogen Marburg (Fig lD, lane 2) contains albumin whereas normal fibrinogen (lane 1) does not. Because normal fibrinogen was purified in exactly the same way as fibrinogen Marburg, it is unlikely that the presence of albumin is caused by a purification artifact. To determine whether fibrinogen Marburg-albumin complexes are present in plasma, normal plasma and plasma of the propositus were run on 2% to 16% precast gradient SDS-PAGE gels (Pharmacia) followed by immunoblot analysis. The blots incubated with MoAb Y18/HRP showed that normal plasma (Fig 2A, lane  1) contained two intense bands representing high molecular weight fibrinogen (HMW Fbg) and low molecular weight fibrinogen (LMW Fbg)?9.40 Plasma of the propositus contained at least seven bands that cross-reacted with the MoAb (Fig 2A, lane 2) . Five of these were discrete bands with M+ of approximately 270,300,330,370, and 440 x l@3, and two diffuse bands with M 6 of approximately 400 and For personal use only. on April 5, 2017. by guest www.bloodjournal.org From (Fig 2B, lane 2) . Normal plasma did not contain any band that cross-reacted with the g-a-albumin/HRP. The immunoblot analysis of purified fibrinogen Marburg and plasma indicates that fibrinogen Marburg is missing a part of the Aa-chain, which results in the formation of fibrinogen-albumin complexes. This deletion is apparently not located in the amino-terminal part of the Aa-chain of fibrinogen Marburg, because fibrinogen Marburg reacts with MoAb YWHRP.
Coagulation of purified fibrinogen. Clotting of purified fibrinogen Marburg induced by thrombin in the presence of Ca2+ or EDTA (Fig 3) was impaired as compared with normal fibrinogen. The rate of FpA release of fibrinogen suggest that the reduced clotting of fibrinogen Marburg is caused by an impairment in fibrin polymerization.
Amplification and DNA sequence analysis of fibrinogen Aa-chain gene exon V. Based on the evidence from the immunoblot analysis using MoAb Y18/HRP, we amplified the genomic DNA that codes for the carboxyl-terminal amino acids (391 to 625) of the Aa-chain from fibrinogen Marburg. The amplified Aa-chain gene fragments of both normal and Marburg had the size predicted from the genomic DNA sequence. DNA sequence analysis of the amplified fragments showed that the fragment derived from genomic DNA coding for fibrinogen Marburg had a single base mutation (Fig 4) in the codon for lysine at position 461 in the Aci-chain. This mutation changed the codon AAA (Lys) to T M , a stop codon. The normal sequence was not present in fragments amplified from Marburg DNA, indicating that the propositus was homozygous for this mutation. This is in agreement with the absence of normal Aa-chain in fibrinogen Marburg (Fig 1, B and C) . Furthermore, the presence of the stop codon at position 461 in the Aa-chain gene of fibrinogen Marburg is in good agreement with the size of thc Aa-chain of fibrinogen Marburg on SDS-PAGE gels ( Fig 1C) . Determination of free sulfiydryl groups in purified fibrinogen. The mutation in fibrinogen Marburg deletes amino acids 461 to 610 in the Aa-chain, including a cysteine residue at position 472 that normally forms an intramolecular disulfide bond with the cysteine at position 442 in the Aa-chain. To determine the redox state of the cysteine at position 442 in fibrinogen Marburg, the number of free sulfhydryl groups was determined by titration of denatured purified fibrinogen with DTNB (Ellman's reagent). Normal fibrinogen and fibrinogen Marburg did not contain any detectable frec sulfhydryl groups ( < 0.1 mol SH/mol fibrinogen). Binding of endothelial cells to purified fibrinogen. The Arg-Gly-Asp sequence in the carboxyl-terminus of the Aa-chain (residues 572-574) is recognized by intergrin-type receptors on endothelial cells.'* Because this sequence is deleted in fibrinogen Marburg, the binding of endothelial cells to purified fibrinogen was determined. After washing with PBS, approximately 57% of the endothelial cells remained attached to microtiter plate wells coated with normal fibrinogen (Fig 5) . Wells coated with fibrinogen Marburg or BSA retained less than 10% of the endothelial cells after washing with PBS. These results show that endothelial cells bind much more weakly to fibrinogen Marburg than to normal fibrinogen, in agreement with the results of Cheresh et al.'* Detection of mutation in genomic DNA of famib members. The mutation found in the Aa gene fragment of fibrinogen Marburg creates a recognition sequence for the restriction endonuclease Dde I in the mutated Aa gene fragment. The additional Dde I site results in the formation of a 195-bp band for the Aa PCR amplified fragment of Marburg as compared with the 236-bp band for normal Aa PCR amplified fragment. Restriction analysis with Dde I of the amplified fragments (Fig 6) confirmed that the propositus (11.1) was homozygous for the defect. The father (I.l), three sisters (11.2,11.3, and 11.6), and the son (111.2) of the propositus showed both the 195-bp and the 236-bp bands, indicating that they were heterozygous for the mutation. The restriction digests of the other three family membcrs (11.4,IIS. and 111.1) containing only the 236-bp band, were similar to normal. The mother of the propositus (1.2) was not studied, but from examining the hereditary pattern (Fig   bP   N 1.1 11.1 11.2 11.3 11.4 11.5 11. 6 7) it is most likely that she was heterozygous for the mutation. The homozygous propositus is the only individual with clinical symptoms, indicating that fibrinogen Marburg is a clinically recessive dysfibrinogenemia. Detection of abnormal jbrinogen in pfasma of famify members. To determine whether the mutation found in the genomic DNA of the family members corresponded with abnormal fibrinogen in plasma, immunoblot analysis of reduced plasma samples was performed using MoAb Y18/ HRP (Fig 8) . Reduced normal plasma contained one intense band corresponding to intact Aa-chain of normal fibrinogen and several faint bands with lower M,s. The propositus (11.1) contained one intense band corresponding to the shorter Aa-chain of fibrinogen Marburg and one faint band with a much lower M,. The heterozygous family members (1.1, 11.2, 11.3, 11.6, and 111. 2) all showed two intense bands corresponding to normal and Marburg Aachain. The three normal family members (11.4, 11.5, and 111.1) only contained the intense band corresponding to normal Aa-chain. The difference in intensity between the normal Aa-chain band and the Marburg Aa-chain band on the immunoblot (Fig 8) suggested that the amount of abnormal fibrinogen present in the heterozygous individuals was substantially smaller than the amount of normal fibrinogen concentration.
NORMAL MARBURG G A T C G A T C
To quantitate the amount of normal and abnormal fibrinogen in plasma of the heterozygous individuals, plasma fibrinogen concentrations were determined by enzyme immunoassays, using MoAb Y18 as a capture antibody and MoAb G8/HRP or r-a-Fbg/HRP for detection (Table 2 ). When plasma of normal family members was analyzed, the fibrinogen concentrations measured by the two EIAs was virtually the same. The results obtained with plasma of the propositus (11.1) show that cross-reactivity with MoAb GS/HRPwas undetectable with fibrinogen Marburg (<0.05 mg/mL), whcreas the EIA combining MoAb Y18 and r-a-Fbg/HRP gave a similar value to that determined by radial immunodiffusion (Table 1) . These results indicate that MoAb G8 does not react with fibrinogen Marburg, which is in good agreement with the results of Hoegee-de Nobel et al,z6 who localized the epitope for MoAb G8 in the carboxyl-terminus of the Aa-chain. Analysis of the heterozygous family members showed that the plasma fibrinogen levels measured by the MoAb Y18-MoAb G8/HRP EIA were only 10% to 20% lower than those determined by the MoAb YlS-r-a-Fbg/HRP EIA. This small difference indicates that in heterozygous individuals the majority (80% to 90%) of the plasma fibrinogen molecules is normal, which is in agreement with the results of the immunoblot analysis (Fig 8) . Furthermore, the total fibrinogen concentration in plasma of heterozygous family members (1.7 to 2.1 mg/mL) was slightly lower than that in plasma of normal individuals (2.5 to 2.9 mg/mL). The plasma thrombin clotting times in the heterozygous family members (23 to 27 seconds) were slightly prolonged compared with those of normal individuals (18 to 20 seconds), indicating that the abnormal fibrinogen molecules inhibited the clotting of normal fibrinogen.
DISCUSSION
SDS-PAGE and immunoblot analysis of the abnormal fibrinogen Marburg showed that this fibrinogen (11.1) contained a shorter Aa-chain polypeptide that we thought arose from a deletion in the carboxyl-terminus. Following this evidence, we amplified the genomic DNA of the propositus that codes for the carboxyl-terminus of the Act-chain from amino acid 391 through the stop codon. Sequence analysis of the amplified fragment showed that the propositus was homozygous for a single base substitution (A + T) in the codon for Aa Lys 461 (AAA) resulting in a stop codon (TAA) at this position. The mutation in the Aathain gene of fibrinogen Marburg predicts an abnormal fibrinogen with an M, of approximately 300,000, containing a shorter Aa-chain with an M, of approximately 47,000, consistent with our protein gel analysis.
Coagulation studies on purified fibrinogen Marburg (11.1) indicate that the deleted Aa-segment contains residues critical for fibrin polymerization. We found that thrombincatalyzed clotting was impaired while FpA release was normal, as is expected for defective fibrin polymerization. This is consistent with the report of Hasegawa and Sasaki,Io who showed that reaggregation of fibrin monomers prepared from purified LMW Fbg (fraction F2) was abnormal in morphology, turbidity, elasticity, and clotting velocity. 1, 11.2, 11.3, 11.4, 11.5, 11.6, 111.1, and 111. 2) after electrophoresis on a 10% SDS-PAGE gel and incubation with MoAb Y18/HRP, an MoAb specific for fibrinogen. 44 The presence of these fibrinogen-albumin complexes severely complicates a specific structure-function interpretation because the disulphide-linked albumin could affect the fibrin polymerization and interaction with endothelial cells by steric hinderance. The absence of free sulfhydryl groups suggests that the unpaired cysteines in fibrinogen Marburg, which are not linked to albumin, are linked to other small molecules as was reported for fibrinogen Osaka IPS or form intramolecular disulfide bonds between the two sulfhydryl groups as demonstrated for fibrinogens Metz14 and Kawaguchi. 15 The presence of the mutation in the genomic DNA of the family members was determined by restriction analysis of the amplified DNA fragment coding for the carboxylterminus of the Aa-chain. The plasmas of the five heterozygous individuals (1.1, 11.2, 11.3, 11.6, and 111.2) contained abnormal fibrinogen. However, in the heterozygous family members the concentration of abnormal fibrinogen was less than 10% to 20% of the total fibrinogen concentration. The plasma fibrinogen concentration of the homozygous propositus was also very low (0.6 mg/mL). These low values of fibrinogen Marburg in plasma indicate that the synthesis, assembly, secretion, and/or plasma lifetime of fibrinogen Marburg is decreased. A decrease in plasma lifetime has been reported for fibrinogen Philadel~hia?~ for which the structural defect is not yet known.
The clinical symptoms of the propositus consisted of severe hemorrhage after delivery followed by repeated thrombotic events. The severe hemorrhage may be explained by the low fibrinogen concentration and the impaired clotting of fibrinogen Marburg. To explain the repeated thrombotic events, we postulate that fibrinolysis of fibrin Marburg is impaired. The role of the carboxylterminus of the Aa-chain in the stimulatory effect of fibrin on tissue-type plasminogen activator-induced plasminogen activation has been previously
The absence of clinical symptoms in the heterozygous family members is probably caused by the relatively low concentration of abnormal fibrinogen in the plasma of these individuals. From these results we can conclude that fibrinogen Marburg (Aa 461 Lys + Stop) is a clinically recessive hypodysfibrinogenemia.
